Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2023-03-15 00:00:00 ET · period of report 2023-03-13 · accession 0001209191-23-018875 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-15 | 2023-03-13 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.51 | +2,291 | 25.6K | +10% | +$1,168 |
| D | 2023-03-15 | 2023-03-13 | TRVI | Delfini Lisa | CFO | S - Sale+OE | $1.75 | -892 | 24.7K | -3% | -$1,561 |
| D | 2023-03-15 | 2023-03-13 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.00 | -2,291 | 80.2K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-13 | M | A | 2,291 | $0.51 | 25,629 | D | — | — | (F2) Includes 4,312 shares purchased through the Issuer's employee stock purchase plan. |
| 2 | Common | Common Stock | 2023-03-13 | S | D | 892 | $1.75 | 24,737 | D | — | — | (F2) Includes 4,312 shares purchased through the Issuer's employee stock purchase plan. |
| 3 | Derivative | Stock Option (right to buy) | 2023-03-13 | M | D | 2,291 | $0.00 | 80,209 | D | $0.51 · — to 2032-02-10 | 2,291 Common Stock | (F4) This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |